



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited

Investor Presentation

Q4 & FY22

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Vijaya Diagnostic Centre Limited (the ‘Company’)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



**VIJAYA
DIAGNOSTIC
CENTRE**

Q4 & FY22 Financial Performance

Q4 & FY22 – Performance Snapshot


Operational & Financial Highlights – Q4 FY22

 2.45 Mn Tests 0.96 Mn Footfalls	 INR 1,162.0 Mn Revenue
 95 Centres (opened 6)	 INR 478.6 Mn EBIDTA 41.2% EBIDTA Margin
 95% B2C Revenue	 INR 237.1 Mn Profit After Tax 20.4% PAT Margin


Operational & Financial Highlights – FY22

 9.32 Mn Tests 3.62 Mn Footfalls	 INR 4,623.7 Mn Revenue
 95 Centres (opened 15)	 INR 2,036.9 Mn EBIDTA 44.1% EBIDTA Margin
 94% B2C Revenue	 INR 1,096.8 Mn Profit After Tax 23.7% PAT Margin

Key Operational Highlights (1/2)




Key Operational Highlights (2/2)



Revenue – COVID, COVID Allied and Non-COVID

(INR Mn)



*COVID revenue includes RT-PCR, Antibody tests and COVID Allied tests like IL-6 and D- Dimer



Key Financial Highlights

(INR Mn)



Annual

Quarterly



Revenue from Operations



EBITDA & EBITDA Margin (%)



PAT & PAT Margin (%)



Consolidated Profit & Loss Account – Q4 & FY22

(INR Mn)

Particulars	Q4FY22	Q4FY21	Y-o-Y	Q3FY22	Q-o-Q	FY22	FY21	Y-o-Y
Revenue from operations	1,162.0	1,120.1	4%	1,107.8	5%	4,623.7	3,767.5	23%
Cost of materials consumed	178.8	162.6	10%	163.0	10%	715.0	570.9	25%
Employee benefits expense	192.0	151.7	27%	182.2	5%	706.6	574.3	23%
Other expenses	312.7	261.5	20%	284.3	10%	1,165.2	962.4	21%
EBITDA	478.6	544.2	-12%	478.3	0%	2,036.9	1,659.7	23%
EBITDA Margin (%)	41.2%	48.6%		43.2%		44.1%	44.1%	
Other income	31.9	42.1	-24%	32.0	0%	128.3	118.5	8%
Depreciation and amortization expense	152.8	125.5	22%	130.1	17%	526.9	504.5	4%
EBIT	357.7	460.8	-22%	380.2	-6%	1,638.3	1,273.7	29%
Finance costs	43.4	34.7	25%	41.8	4%	164.5	152.5	8%
Profit before Tax	314.3	426.1	-26%	338.5	-7%	1,473.8	1,121.2	31%
Tax expenses	75.5	109.2	-31%	83.9	-10%	367.2	270.0	36%
Profit before Minority Interest	238.8	316.8	-25%	254.6	-6%	1,106.7	851.3	30%
Minority Interest	1.7	2.7	-36%	1.7	-2%	9.9	6.5	52%
Profit after Tax (PAT)	237.1	314.2	-25%	252.9	-6%	1,096.8	844.8	30%
PAT Margin (%)	20.4%	28.0%		22.8%		23.7%	22.4%	
EPS – Basic (INR)*	2.33	3.08		2.48		10.76	8.28	

*Not annualized



**VIJAYA
DIAGNOSTIC
CENTRE**


Company Overview

Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 95 state-of-the-art centres spread across 16 cities



Mission

Our Mission is to make the patient’s medical journey faster, more transparent and more accurate. We are committed to deliver exceptional diagnostic solutions to every patient and physician



Vision

Our Vision is to provide reliable and accurate diagnostic services to our customers, at affordable prices, in a customer-centric manner. We strive to provide the best service possible. We are continually raising our own bar through the latest technology, continuous improvement and recruitment of high calibre technicians and professional



40+
Years of Experience

Experience in delivering Quality Diagnostic Service at affordable prices



95
Centres

State-of-the-art Facilities with Best-in-class Technology



Quality



16
Cities across India
Largest integrated player in South India



200+
Doctors
Radiologists, Pathologists & Microbiologists



Reliable & Accurate Diagnostics




~3.6 Mn
Footfalls
Trusted by every Age group



~9.3 Mn
Tests
Most preferred Diagnostic Centre




at Affordable Prices



*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

At the Forefront of Introducing New Technologies




Our Pillars of Strength



Indian Diagnostics Market expected to Grow at a Healthy Trajectory


Indian Diagnostics Market

(INR Bn)




Segment-wise breakup of Indian Diagnostic Market

Radiology Pathology




One of the leading players in India's high growth diagnostics market




Growth Drivers:

- Rising NCDs in the states
- Increasing share of aged population
- Rising health awareness
- Increasing health insurance penetration
- Conducive government healthcare schemes



Integrated Diagnostic service provider with extensive network...



Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT)
Hubs = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT)
Diagnostic Centre / spokes = Lab Samples Collection + Basic Radiology
Basic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.

Complete Range of Diagnostic Services under One Roof


Comprehensive and high quality integrated diagnostic services through our operational network



High brand recall driving customer stickiness

Customer Centric Approach

Quality Diagnostic Services



Higher brand recall


High share of walk-in customers

Sticky individual customer


“One of the Best Healthcare Brands 2021”
by The Economic Times in 2021

“For excellence in Quality and Accuracy”
under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021


B2C Revenue



Operational Metrics



Robust Technical Capabilities with State-of-the-art IT Infrastructure



Key Suppliers



- Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Advanced Software to Manage Clinical Data



Advance Laboratory Information Management System (LIMS)



Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling...



Standardization across our operations



Closely track key performance metrics and maintain the **Turn-Around Time (TAT)**



Reduce incidence of errors due to **Low Human Intervention**



Provide **Uniform Experience** to customers from booking appointments to accessing reports online



Monitor Technical Operations

Experienced Board of Directors



Dr. S Surendranath Reddy - Executive Chairman

- Founder of Vijaya with 40+ years of experience in building Vijaya as South India's largest integrated diagnostic chain
- Holds Bachelor's degree in Medicine and Provisional degree of Doctor of Medicine in Radiology



S Geeta Reddy - Non-Executive Director

- Enrolled as advocate with Andhra Pradesh High Court in 1986
- Holds a Bachelor's degree in Law from Osmania University



Sunil Chandra Kondapally - Executive Director

- Been with Vijaya since 2002 and 17+ years of experience in healthcare
- Holds Bachelor's degree in Electrical Engineering from Florida State University



Dr. D Nageshwar Reddy - Non-executive, Independent Director

- Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad
- Awarded Padma Shri and Padma Bhushan by Government of India
- D.M in Gastroenterology from PGIMER Chandigarh



Shekhar Prasad Singh - Non-executive, Independent Director

- Ex-Chief Secretary to Government of Telangana
- Retired IAS officer of 1983 batch



Satyanaryana Murthy Chavali - Non-executive, Independent Director

- Ex-CEO of Aurigene Discovery Technologies Ltd.
- Holds BTech from IIT, Madras and MBA from IIM, Bangalore



Dr. Manjula Anagani - Non-executive, Independent Director

- Clinical Director and Head of Department of centre of women and childcare at Care hospitals
- Awarded Padma Shri by Government of India
- MD in Obstetrics and Gynecology from N.T.R. University of Health Sciences

Strong Management Team



Dr. S. Surendranath Reddy

Executive Chairman

- 40+ years of experience in building Vijaya as South India's largest integrated diagnostic chain
- Holds Bachelor's degree in Medicine and Provisional degree of Doctor of Medicine in Radiology
- He is a life member of the Indian Radiological and Imaging Association.



Mr. Sunil Chandra Kondapally

Executive Director

- With Vijaya since incorporation and experienced in operations, quality accreditation, finance, marketing and network expansion departments
- 17+ Years of experience in healthcare industry & founded Trikona Pharmaceuticals Pvt. Ltd. (2016) and QPS Bioserve India Pvt. Ltd. (2004)
- Holds bachelor's degree in electrical engineering from Florida State University



Ms. Suprita Reddy

Chief Executive Officer

- With Vijaya since 2003 and heads overall strategy, clinical excellence, operations and expansion of the company
- Awarded Women Leadership Award in Healthcare by ABP in 2019
- Holds bachelors degree in commerce from Osmania University



Mr. Narasimha Raju K.A

Chief Financial Officer

- Associated with Vijaya from June 2017 to Nov 2020 and rejoined in March 2021
- 14+ years of experience in audit, financial reporting, regulatory compliance and accounting advisory
- Previously worked with SR Baltiboi & Co., NSL Renewable Power Pvt. Ltd. etc
- Holds bachelor's degree of commerce from Osmania University and member of the Institute of Chartered Accountants of India



Ms. Anusha Kanumuru

Company Secretary & Compliance Officer

- 12 + years of experience in handling works relating to public issue(s), private placement(s), merger(s), foreign investment, listing formalities with the Stock Exchanges, Company Law, FEMA and Stock Exchange Compliances including regulatory approvals
- Associate member of ICSI and holds Bachelor's degree in Commerce and Corporate Affairs
- Previously worked with Aurobindo Realty, IVRCL Ltd etc

Awards & Accolades

One of the Best Healthcare Brands 2021



2021
Presented by
The Economic
Times

Indo Global Award for Healthcare Excellence



2021
Presented by
Indian Economic
Development &
Research Association

Company of the Year - Healthcare



2021
Presented by
TV9 Network and SAP

Leading Diagnostic Chain of the Year



2021
Presented by
Diagnostic Leadership
Summit

India's Greatest Leaders 2020-21 Ms. Suprita Reddy - CEO



2021
Presented by
United Research
Services

India's Greatest Brands 2020-21 Pride of Nation



2021
Presented by
United Research
Services

Leading Diagnostics with Excellence in Quality & Safety



2021
Presented by
Diagnostic
Leadership Summit

Most Trusted and Best Quality Diagnostic services in India




2020
Presented by
Times Healthcare
Achievers

Healthcare Entrepreneur of the Year – Dr. Surendra Reddy



2019
Presented by
Six Sigma
Healthcare

Fastest Growing Brands (Pride of the Nation)



2019
Presented by
United Research
Services

Best Diagnostic Centre of the Year



2019
Presented by
Times Healthcare
Achievers

Leading Chain of Diagnostics & Imaging



2019
Presented by
Indian Medical
Association,
Telangana state and
Messe India

Best Diagnostic Service Provider of the Year



2019
Presented by
Six Sigma
Healthcare

Most Trusted Diagnostic Centre of the Year




2019
Presented by
Indo-Arab
Leaders
Summit &
Awards

Telangana Healthcare Leadership Awards



2018
Presented by
Telangana
Government



Shareholding Pattern as of 31st March 2022

Category	% Holding
Fidelity Group#^	9.1%
Wasatch Advisors^	7.9%
Axis Mutual Fund^	6.6%
Aberdeen Standard Investments^	5.8%
Nippon Life India Asset Management^	2.2%
Aditya Birla Sun Life Asset Management^	1.9%
Abu Dhabi Investment Authority	1.0%
DSP Mutual Fund	1.0%

As on 31st Mar 2022
DII's: Mutual Funds, AIF's and QIB's
Others: Retail, Bodies Corporate and others


^holding through various schemes/funds
Fidelity International Limited (FIL) and Fidelity Management and Research Company (FMR)



**VIJAYA
DIAGNOSTIC
CENTRE**

Strategy Going Forward

Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh



Leveraging Existing Presence

Given under-penetration of diagnostic market, we will continue to focus on



Opening additional diagnostic centres through owned & franchisee model



Expanding network through setting up spokes and hubs in existing catchment areas



Adding reference laboratories in our existing core geographies



Consolidate Leading Position

Given our significant presence and operational experience in Telangana and Andhra Pradesh, we intend to deepen our penetration and increase customer base by



Enhancing laboratory capacity and test menu by adding latest technologies




Offering value added services



Physician engagements (by conducting continuous medical education programs)

Expand in Adjacent Geographies & East India

Network (FY22)




South India Strategy

- Expand in concentric circles given our hub and spoke model
- Establish presence in adjacent geographies
- Identified key cities and towns which are underserved and our brand is well-regarded
- Wider geographic reach will expand our customer base leading to better profitability by leveraging our infrastructure

East India Strategy

- Expand presence in East India given growing demand
- Replicate our successful hub and spokes model in East India
- Established a hub in Kolkata and plan is to set up additional diagnostic centres around it
- Hence, Kolkata to be our focus area for medium to long term growth

Preventive and Wellness Testing to Boost Demand for Diagnostics



Key Drivers

- Increasing chronic and lifestyle diseases
- Corporate tie-ups
- Increasing disposable income
- Increasing service offerings

Our Strategy


- Increase diagnostic services by offering additional preventive and wellness services through adoption of new cutting-edge diagnostic testing technology
- Providing home collection services and point-of-contact testing to complement walk-in
- Expand specialty tests, disease specific profiles and provide customized packages
- Grow our corporate customer base by catering to their needs
- Expansion of chronic disease management and wellness programs




**VIJAYA
DIAGNOSTIC
CENTRE**

Financial & Operational Highlights


Diagnostic Centre (Nos)



Footfalls (Mn)




Tests Performed (Mn)




Test per Footfall (Nos)


Impact of COVID-19



Revenue per Test (INR)




Revenue per Footfall (INR)




Consistent Financial Performance

(INR Mn)


Revenue




EBIDTA




PAT



EBIDTA Margin (%)




PAT Margin (%)




Sustainable Cash Generation & Increasing Return Ratios

Cash & Cash Equivalents


(INR Mn)




CFO / EBITDA (%)



RoCE Pre-Cash (%)



RoE (%)





**VIJAYA
DIAGNOSTIC
CENTRE**

Annexure

Consolidated Profit & Loss Account

(INR Mn)

Particulars	FY22	FY21	FY20	FY19
Revenue from operations	4,624	3,767	3,388	2,926
Cost of materials consumed	715	571	439	405
Employee benefits expense	707	574	624	539
Other expenses	1,165	962	999	901
EBITDA	2,037	1,660	1,326	1,081
EBITDA %	44.1%	44.1%	39.1%	37.0%
Other income	128	118	154	104
Depreciation and amortization expense	527	505	492	396
EBIT	1,638	1,274	988	789
Finance costs	165	152	154	135
Profit before Tax	1,474	1,121	834	653
Tax expenses	367	270	209	190
Profit after Tax before Minority Interest	1,107	851	625	463
Minority Interest	10	6	0	4
Profit after Tax	1,097	845	625	459
PAT %	23.7%	22.4%	18.5%	15.7%
EPS – Basic (INR)	10.76	8.28	6.13	4.50

Consolidated Balance Sheet

(INR Mn)

Assets	Mar-22	Mar-21	Mar-20	Mar-19
NON-CURRENT ASSETS	4,436	3,022	2,959	2,689
Property, plant and equipment	1,966	1,358	1,398	1,437
Capital work-in-progress	341	82	93	27
Goodwill	53	53	53	69
Other intangible assets	14	6	10	7
Right of use asset	1,672	1,260	1,254	1,079
Intangible assets under development	1	12	4	-
Financial assets				
- Investments	0	0	0	0
- Other financial assets	75	122	55	43
Deferred tax assets	89	61	16	12
Income tax assets	2	6	9	8
Other assets	223	61	67	7
CURRENT ASSETS	2,699	2,388	1,865	1,374
Inventories	43	26	28	22
Financial assets				
- Investments	542	276	547	688
- Trade receivables	98	64	80	91
- Cash and cash equivalents	110	67	556	96
- Bank balances other than Cash and cash equivalents	1,813	1,876	626	430
- Loans	0	0	1	4
- Other financial assets	51	52	5	26
Other current assets	41	27	22	17
TOTAL ASSETS	7,135	5,409	4,824	4,063

EQUITY AND LIABILITIES	Mar-22	Mar-21	Mar-20	Mar-19
EQUITY	4,695	3,592	2,741	2,069
Equity share capital	102	45	45	45
Instruments entirely equity in nature	-	-	-	24
Other equity	4,593	3,547	2,696	2,000
NON-CURRENT LIABILITIES	1,778	1,377	1,494	1,422
Financial liabilities				
- Borrowings	0	33	221	315
- Lease liabilities	1,703	1,265	1,196	1,034
- Other financial liabilities	0	2	9	19
Provisions	74	77	67	53
Other liabilities	1	1	1	1
CURRENT LIABILITIES	661	440	589	572
Financial liabilities				
- Borrowings	6	12	13	20
- Lease liabilities	126	101	88	73
- Trade payables	216	222	217	218
- Other financial liabilities	248	61	224	204
Income tax liabilities	9	16	15	15
Provisions	21	7	11	11
Other liabilities	35	20	21	31
TOTAL EQUITY AND LIABILITIES	7,135	5,409	4,824	4,063

Consolidated Cash Flow Statement

(INR Mn)

Particulars	Mar-22	Mar-21	Mar-20	Mar-19
Cash Flow from Operating Activities				
Profit before Tax	1,474	1,121	834	653
Adjustment for Non-Operating Items	572	534	492	431
Operating Profit before Working Capital Changes	2,046	1,655	1,326	1,084
Changes in Working Capital	-67	-46	-32	8
Cash Generated from Operations	1,975	1,609	1,294	1,092
Less: Direct Taxes paid	-399	-312	-233	-187
Net Cash from Operating Activities	1,580	1,297	1,061	905
Purchase and construction of property, plant and building (net)	-1,223	-312	-375	-591
Investments (net)	-127	-1,033	11	-314
Others	120	47	57	6
Cash Flow from Investing Activities	-1,226	-1,298	-306	-898
Cash Flow from Financing Activities	-306	-488	-295	-72
Net increase/ (decrease) in Cash & Cash equivalent	44	-489	460	-65
Cash & Cash Equivalents at the beginning of the period	67	556	96	161
Cash & Cash equivalents at the end of the period	110	67	556	96

Cash and Cash Equivalents

Particulars	Mar-22	Mar-21	Mar-20	Mar-19
Investments*	543	335	547	688
Cash and cash equivalents	110	67	556	96
Bank balances other than Cash and cash equivalents	1,813	1,876	626	430
Total	2,467	2,277	1,729	1,215



**VIJAYA
DIAGNOSTIC
CENTRE**



THANK YOU

Company

Vijaya Diagnostic Centre Limited (VDCL)



Mr. Siva Rama Raju – Head of Strategy
+91 90597 00749 / +91 99485 95555

sivaramaraju.v@vijayadiagnostic.in
ir@vijayadiagnostic.in

www.vijayadiagnostic.com

Investor Relations Advisors

Citigate Dewe Rogerson (CDR India)

Mr. Anoop Poojari /
Mr. Devrishi Singh

| Citigate Dewe Rogerson Tel: +91 98330 90434 /
+91 98205 30918

anoop@cdr-india.com
devrishi@cdr-india.com